HK Stock Market Move | Huaxin Building Materials Group (06655) rises more than 5%, the company achieved a counter-cyclical growth in revenue in the third quarter, and overseas production capacity continues to expand.
Huaxin Cement (06655) rose more than 5%, as of the time of this report, it had risen by 4.72% to 18.85 Hong Kong dollars, with a turnover of 68.1061 million Hong Kong dollars.
Huaxin Building Materials Group (06655) rose by more than 5%, closing at a 4.72% increase to HKD 18.85 by the time of publication, with a trading volume of 681.061 million Hong Kong dollars.
On the news front, recently, Huaxin Building Materials Group announced that in the first three quarters of 2025, its operating income was RMB 25.033 billion, a year-on-year increase of 1.27%; net profit attributable to shareholders of the listed company was RMB 2.004 billion, a year-on-year increase of 76.01%; and basic earnings per share was RMB 0.97. Tianfeng pointed out that the company's operating income in the third quarter increased by +1.1% month-on-month, achieving a counter-cyclical growth, mainly due to the contribution of overseas business. The company's acquisition of assets in Nigeria from Hourui was completed through equity transfer on August 29, with an expected increase in contribution in September.
The bank continued to point out that by the end of the first half of 2025, the company had established production bases in 12 overseas countries, with overseas cement grinding production capacity reaching 24.7 million tons per year, and with the completion and consolidation of the cement production capacity in Nigeria, it may have reached 35.3 million tons, with a total of approximately 1.55 million tons/year of clinker capacity under construction. The 2,000-ton clinker cement production line project in Malawi successfully ignited on September 28, further consolidating the company's overseas competitiveness.
Related Articles

SHINEWAY PHARM (02877) had a revenue of 2.415 billion RMB in the first three quarters, a decrease of 16.3% year-on-year.

FIRST PACIFIC (00142) has completed the proposed demerger of MAYNILAD WATER SERVICES, INC. and will independently list on the Philippine Stock Exchange.

BOAN BIOTECH (06955): Two types of Dexu Monoclonal Antibody Injections have been accepted for market approval in the United Kingdom.
SHINEWAY PHARM (02877) had a revenue of 2.415 billion RMB in the first three quarters, a decrease of 16.3% year-on-year.

FIRST PACIFIC (00142) has completed the proposed demerger of MAYNILAD WATER SERVICES, INC. and will independently list on the Philippine Stock Exchange.

BOAN BIOTECH (06955): Two types of Dexu Monoclonal Antibody Injections have been accepted for market approval in the United Kingdom.

RECOMMEND

SERES Faces Market Test in Hong Kong: Shares Open Below Issue Price Despite HK$220 Billion Market Valuation
06/11/2025

Copper Prices Surge While Former “Copper King” Who Outpaced Huawei and Tencent Falls into Decline
06/11/2025

National Energy Administration Reports New-Type Energy Storage Capacity Exceeds 100 Million Kilowatts by End‑September
06/11/2025


